Mutations affecting the expression of the Janus family kinase JAK3 were recently shown to be responsible for autosomal recessive severe combined immunodeficiency (SCID). JAK3-deficient patients present with a clinical phenotype virtually indistinguishable from boys affected by X-linked SCID, a disease caused by genetic defects of the common gamma chain (%) that is a shared component of the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15. The specific interaction of JAK3 and ~/c represents the biochemical basis for the similarities between these two immunodeficiencies. Both forms of SCID are characterized by recurrent, severe infections leading to death in infancy unless successfully treated by allogeneic bone marrow transplantation. Because of the potentially lethal complications associated with allogeneic bone marrow transplantation and the frequent lack of suitable marrow donors, the development of alternative forms of therapy is highly desirable. To this end, we investigated a retroviral-mediated gene correction approach for JAK3-deficiency. A vector carrying a copy ofJAK3 cDNA was constructed and used to transduce B cell lines derived from patients with JAK3-deficient SCID. We demonstrate restoration of JAK3 expression and phosphorylation upon IL-2 and IL-4 stimulation. Furthermore, patients' cells transduced with JAK3 acquired the ability to proliferate normally in response to IL-2. These data indicate that the biological defects of JAK3-deficient cells can be efficiently corrected in vitro by retroviral-mediated gene transfer, thus providing the basis for future investigation of gene therapy as treatment for JAK3-deficient SCID.
J
anus kinases (JAK1, JAK2, TYK2, and the recently identified JAK3) are a family of nonreceptor protein tyrosine kinases involved in intracellular signal transduction mediated by various cytokines, interferons, and growth factors (1, 2) . JAK3, unlike the other Janus kinase family members, has an expression pattern restricted to lymphoid and myeloid tissues (3) , and appears to play a critical role in cytokine signaling through specific association with the common gamma chain (%) of the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15 (4) (5) (6) (7) (8) (9) (10) (11) . JAK3 is activated and phosphorylated upon ligand binding to ~/c-containing receptors (12) (13) (14) , an event leading to phosphorylation of several other proteins (including JAK1 and signal transducers and activators of transcription [STATs] ), and eventually gene activation (15) .
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Several lines of evidence have recently underscored the biological relevance of JAK3 and its interaction with % for development and maturation of lymphoid tissues. First, mutations in % have been shown to result in X-linked SCID (XSCID) (16, 17) , a congenital defect of immunity typically characterized by severe T cell lymphopenia, nonfunctional B cells, hypoplastic lymphoid organs, and extreme susceptibility to opportunistic infections leading to death early in life (18) . Subsequent studies demonstrated that % mutations responsible for "classical" XSCID phenotype resulted in complete disruption of %-JAK3 interaction, while a specific point mutation in % associated with a milder form of combined immunodeficiency was shown to result in a severely diminished, but not completely abrogated, association of JAK3 with % (11) . From this evidence it was postulated that mutations affecting JAK3 function could produce an autosomal form of inherited immunode-ficiency resembling the XSCID phenotype. Most recently, in agreement with this prediction, two independent groups identified genetic defects of JAK3 in patients affected by a congenital form of immunodeficiency with cellular and biological characteristics virtually identical to those seen in XSCID, but transmitted as an autosomal recessive trait (19, 20) .
After the original reports, additional SCID patients carrying abnormalities of JAK3 expression were identified (Notarangelo, L.D., unpublished observations), defining JAK3-deficient SCID (JAK3-SCID) as a separate nosological entity. On the other hand, because of the clinical similarities existing between JAK3-SCID and XSCID (19, 20) , the medical management is identical for both forms ofimmunodeficiency, and allogeneic bone marrow transplantation (BMT) is currently the only curative treatment available. BMT, however, is an intensive procedure potentially associated with severe complications such as graft versus host reactions (GVHD) (21), and is not an available option for many patients because of lack of suitable marrow donors. For these reasons, the investigation of alternative therapeutic strategies is needed, and the development of gene-based therapies would be beneficial for those cases where traditional treatment is not available.
To investigate a gene therapy approach for JAK3-SCID, we constructed a retroviral vector containing the normal JAK3 cDNA sequence and used it to reconstitute the expression of JAK3 protein in B cell lines from JAK3-SCID patients. We show that the transgenic JAK3 was expressed at levels comparable to those found in B lymphoblastoid cells from normal donors. Further, we show that the newly expressed JAK3 kinase was phosphorylated upon IL-2 and IL-4 stimulation, and that IL-2-mediated cell proliferation was restored to nearly normal levels in JAK3-transduced cells. This study demonstrates that biological functions affected in JAK3-deficient cells can be corrected in vitro by retroviral-mediated gene transfer and suggests the potential application ofgene transfer as therapy forJAK3-SCID.
"micro ping-pong" technique (26) from PA317 and GP+E-86 cells and used to infect the gibbon-ape leukemia virus (GALV)-based PG13 packaging line. PG13-derived viral particles were then used for subsequent transduction of JAK3-SCID as previously described (27) . Transfected and transduced cells were subjected to selection with 0.8-1.0 mg/ml of the neomycin analogue G418 (Geneticin; Life Technologies).
Western Protein Analysis. Cells were lysed in buffer containing 300 mM NaC1, 50 mM Tris-HCl, 2 mM EDTA, 0.5% Triton X-100, 2.5 p~M p-nitrophenyl p "guanidino-benzoate, 10 p~g/ml aprotinin, and 10 ~g/ml leupeptin. Lysates (100 I.zg of protein) were centrifuged at 12,000 g, boiled, subjected to 8% SDS-PAGE, and electro-transferred onto nylon membranes (Immobilon-P; Millipore, Bedford, MA). Membranes were incubated with a rabbit polyclonal Ab directed against the COOH terminus of JAK3 0x-JAK3) (3) or a mouse monoclonal Ab specific forJAK1 (oe-JAK1; Transduction Laboratories, Lexington, KY) following previously reported procedures (12) .
Immunoprecipitation. Cells (5-10 X 107) were cultured in RPMI 1640 without FBS for 4 h, stimulated with IL-2 (1,000 U/m/) or IL-4 (1,000 U/ml) for 15 min, and then lysed in the above defined lysis buffer supplemented with 200 p~M sodium orthovanadate. After centrifugation, postnuclear supernatants were immunoprecipitated with c~-JAK3, washed, boiled, and resolved using SDS-PAGE electrophoresis. Immunoprecipitated complexes were immunoblotted with anti-phosphotyrosine mouse monoclonal Ab (o~-PY, 4G10; Upstate Biotechnology Inc., Lake Placid, NY) or o~-JAK3 as described (12) . Detection was then performed by enhanced chemiluminescence (ECL; Amersham Corp., Arlington Heights, IL).
Proliferative Response to IL-2. Cells were incubated in RPMI 1640 supplemented with 0.5% FBS for 24 h. Cells (2 • 104/well) were then plated onto 96-well plates and incubated for 24 h in RPMI with or without 2.5-5 X 10 -7 M IL-2. Tridated thymidine ([3H]-Tdr, 1 ~Ci/well; NEN-Dupont, Boston, MA) was then added to microcultures and incubated for an additional 6 h. Cells were harvested with an automated cell harvester (XVallac, Uppsala, Sweden) and transferred to filters. DNA-incorporated radioactivity was determined using a liquid scintillation counter. 1Le-suits are given as average of six replicates. Stimulation index was calculated as the ratio of [3H]-Tdr incorporated in the presence of RPMI medium supplemented with IL-2 divided by that incorporated in RPMI medium without IL-2 supplementation.
Materials and Methods
Patients and Cell Lines. C.M. and C.A. are JAK3-SCID siblings from consanguineous parents whose mutation has been previously reported (19) . Peripheral blood was obtained upon parental informed consent from both patients and normal donors and B cell lines (BCLs) were established by standard Epstein-Barr virus immortalization. Cells were maintained in RPMI 1640 (GIBCO BRL, Gaithersburg, MD), and cultured at 37~ 5% CO 2. PA317 (22) , PG13 (23) , and GP+E-86 (24) retrovirus-packaging lines were cultured in Dulbecco's modified Eagle's minimum essential medium (DME; Biofluids, Ikockville, MD), at 37~ 10% CO 2. All tissue culture media were supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT), 2 mM L-glutamine (GIBCO BRL), and 50 txg/ml gentamycin (Bio-Whittaker, Walkersviile, MD).
Retroviral Construct and Transduction Procedures. A copy of JAK3 cDNA (3) was subcloned using the Not/and SnaBI sites into the pSAM-EN retroviral cassette by standard molecular biology techniques (25) . Amphotropic supernatants were produced by the
Results and Discussion
Retroviral-mediated Expression of JAK3. A 3.5-kb fragment containing the full-length JAK3 open reading frame was subcloned into pSAM-EN retroviral cassette to obtain the pGCJ3 vector (Fig. 1) . This vector was packaged into GALV envelope expressing retroviral particles using the PG13 packaging cell line since this envelope protein results in higher rates of retroviral transduction of lymphoid cells (28) . Supernatants containing retroviral particles were then used to transduce JAK3-deficient BCLs by exposure for 24 h in presence of 10 p,g/ml protamine. After G418 selection, the transduced cells were assessed for JAK3 protein expression. Fig. 2 (upper panel) shows the results of Western analysis on whole cell lysates obtained from normal BCLs (lane 1), patients C.M. and C.A. before (lanes 2 and 5, respectively) and after transduction with GCJ3 (lanes 4 and 6, respec- (Fig. 3, top) . Normal donor BCLs (lanes 1-3) , untransduced (lanes 4-6), and JAK3-transduced (lanes 7 -9 ) J A K 3 -S C I D patient cells were left unstimulated (lanes 1, 4, and 7) or stimulated with IL-2 (lanes 2, 5, and 8), or IL-4 (lanes 3, 6, and 9). Lysates were immunoprecipitated with ot-JAK3 and immunocomplexes probed with ot-PY. We observed that the transduced JAK3 protein was properly phosphorylated in response to both cytokines, thus demonstrating that the signal generated by IL-2 and IL-4 ligand binding was appropriately transduced to the newly expressed JAK3 protein. The filter was then stripped and reprobed with oL-JAK3 to confirm the presence of JAK3 protein in the immunoprecipitates (Fig. 3,   bottom) . As expected from the absence o f JAK3 in whole cell lysate (Fig. 2, lane 2) , no JAK3 protein was immunodetected in the J A K 3 -S C I D cells before gene transfer (lanes [4] [5] [6] . Taken together these data further suggest that untransduced (4-6) and GCJ3-transduced (lanes 7-9) JAK3-SCID BCLs were stimulated with the indicated cytokine for 15 rain at 37~ lysed, and immunoprecipitated (IP) with 0t-JAK3. Complexes were resolved by SDS-PAGE and detected by immunoblotting (IB) with ot-PY. Membrane was stripped and the presence of JAK3 in immunocomplexes was verified by blotting with ot-JAK3. To determine whether JAK3-SCID BCLs showed reduced proliferation in response to IL-2 and whether JAK3 gene transfer and expression could restore a normal response, we assayed IL-2-induced cell proliferation before and after gene transduction. We previously determined appropriate culture conditions that allowed us to demonstrate a specific proliferative response of BCLs to IL-2 (27) . Using these same conditions, we could detect substantially reduced cell proliferation ofJAK3-SCID BCLs to IL-2 when compared to normal donor BCLs. Moreover, we demonstrated norrealization of IL-2-mediated cell growth after JAK3 gene transfer (Fig. 4) , but not after transduction with the neo control retroviral vector. It should be noted that EBVimmortalized B cell lines are not IL-2 growth dependent, and therefore the effect oflL-2 on cell growth is not as dramatic as it is for primary cells or factor-dependent lines. Nonetheless, lack of proliferation to IL-2 in JAK3-SCID cells confirms the importance of JAK3 for cell cycle progression induced by this cytokine. Furthermore, the restoration of an appropriate proliferative response upon gene correction demonstrates that the exogenously expressed JAK3 protein allowed for proper transduction of the IL-2 signal from receptor to nucleus, leading to transcriptional activation of specific genes responsible for cell growth. Severe combined immunodeficiencies are a heterogeneous group of inherited disorders of immunity characterized by failure to thrive, severe infections, and combined lack of T and B cell functions. Infectious episodes are usually recurrent, life-threatening, and lead to death in early life unless affected patients undergo reconstitution of a normal immune system by allogeneic bone marrow transplantation (31) . Transplantation procedures from HLA-identical siblings usually result in full immune reconstitution of the recipients with minimal risks related to GVHD. In contrast, transplantation from haplo-identical donors or MHCmatched unrelated individuals is characterized by a higher risk of severe GVHD and graft failure (21, 32) . Gene therapy, therefore, could represent a beneficial alternative form of treatment for those patients lacking a suitable marrow donor.
The recent identification of defects in JAK3 protein expression as the cause of an autosomal recessive form of SCID (19, 20) has on the one hand opened the way for a better understanding of the mechanisms involved in lymphocyte development and differentiation, and on the other provided the basis for investigating gene-based therapeutic approaches. We demonstrate here that retroviral-mediated gene transduction could effectively correct several biological defects in B cell lines from JAK3-SCID patients. Because of the lack of mature circulating T cells, these patients are not eligible for a T lymphocyte-directed gene transfer approach as previously used for adenosine deaminase-deficient SCID (33); consequently, corrective gene transfer for JAK3-deficient patients will require targeting of the lympho-hematopoietic stem cell. Retroviral vectors have been demonstrated capable of safely transferring and expressing exogenous genes into hematopoietic progenitors in animal models (34) (35) (36) and humans (37) (38) (39) . It is conceivable, therefore, that the genetic correction and reinfusion of autologous JAK3-deficient lympho-hematopoietic stem cells could provide a means to reconstitute the immune system of JAK3-SCID patients, avoiding the risks of GVHD.
Further studies are necessary to assess whether the "ectopic" expression of retrovirally transduced JAK3 in a stem cell could be deleterious to the normal development of non-lymphoid hematopoietic lineages before a clinical gene therapy protocol for JAK3-SCID could be proposed. As part of pre-clinical investigations, the transfer of the JAK3 gene into the hematopoietic system of animal models would provide important insight into the biological effects of the exogenous expression of JAK3 protein. The recent generation of mice with a targeted deletion of the JAK3 gene (40) (41) (42) constitutes an important model where these critical issues can be conveniently addressed.
Furthermore, the definition of the JAK3 genomic structure (Riedy, M.C., W. Modi, A.S. Dutra, T.B, Blake, B.K. Lal, J. Davis, A. Bosse, J.J. O'Shea, and T.A. Johnston, manuscript submitted for publication) and the future identification of its regulatory region will provide the possibility of constructing gene transfer vectors containing the natural promoter sequences and leading to physiologically controlled JAK3 expression.
